



The Effectiveness of Smoking Cessation Interventions in Smokers with Cerebrovascular Disease: A systematic review and meta-analysis.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002022
Article Type:	Research
Date Submitted by the Author:	29-Aug-2012
Complete List of Authors:	Edjoc, Rojiemiahd; University of Ottawa Heart Institute, Minto Prevention and Rehabilitation Centre Reid, Robert; University of Ottawa Heart Institute, Minto Prevention and Rehabilitation Centre Sharma, Mukul; The Ottawa Hospital, Champlain Regional Stroke Program
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Epidemiology, Smoking and tobacco
Keywords:	EPIDEMIOLOGY, systematic review, meta-analysis, smoking cessation, Stroke < NEUROLOGY

SCHOLARONE™
Manuscripts

The Effectiveness of Smoking Cessation Interventions in Smokers with Cerebrovascular Disease: A systematic review and meta-analysis.

Rojiemiahd K. Edjoc, MSc¹.

Robert D. Reid, Ph.D., MBA¹

Mukul Sharma, MD MSc FRCPC²

¹Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Canada

²Regional Stroke Prevention Program, The Ottawa Hospital, Ottawa, Ontario, Canada

Correspondence to: Rojiemiahd K. Edjoc, MSc. Research Assistant, Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON K1Y 4W7, Canada

Tel: 613-983-4123

Fax: 613-761-4595

e-mail: redjoc@ottawaheart.ca

Key words: Smoking cessation, systematic review, meta-analysis, stroke

Word count: 2128

Abstract

Objective: The main objective of this study was to determine the effectiveness of smoking cessation interventions in increasing cessation rates in smokers with cerebrovascular disease.

Design: Systematic review and meta-analyses. Two independent reviewers searched information sources and assessed studies for inclusion/exclusion criteria.

Eligibility criteria for included studies: Randomized control trials published prior to the 31st December 2011 investigating smoking cessation interventions in smokers with cerebrovascular disease were included. No age or ethnicity limitations were applied to be as inclusive as possible.

Methods: We followed the PRISMA statement approach to identify relevant randomized control studies. We used a mixed effects Mantel-Haenszel approach meta-analysis to pool estimate effects for randomized control trials.

Results: Of 852 identified articles, 4 articles fit the inclusion criteria describing the outcome in 303 patients. The overall cessation rate with a smoking cessation intervention was 28.1% (42/153) while without one was 24.7% (37/150). However, the meta-analysis revealed a non-significant effect of using a smoking cessation intervention on quitting (RR 1.19; 95% CI 0.81 to 1.73; $p=0.38$, $I^2=0.00$).

Conclusions: There is a dearth of intervention studies that explore this area of secondary stroke prevention. Furthermore, of those intervention studies that were found, only two implemented evidence based approaches to smoking cessation. More studies are needed to determine how effective SCI's are in increasing cessation rates in this high risk population of smokers.

ARTICLE SUMMARY

Article focus

- To assess the effectiveness of smoking cessation interventions in smokers with cerebrovascular disease.

Key messages

- There is a limited number of intervention studies that explore this area of stroke prevention.

- Of those intervention studies found, only a handful employed evidence based approaches to smoking cessation.

- The review was underpowered to achieve statistically significant results.

Strengths and limitations of this study

- This is the first review to explore the effectiveness of stop smoking interventions in this high risk group of smokers.

- This review explores the breadth of potential interventions in stroke and TIA patients.

- Limitations of this study include a small number of available studies, large heterogeneity in population, intervention and outcome.

Introduction

Smoking prevalence has decreased in the United States over the last 40 years and as of 2009 approximately 46 million people, or 20.6% of all adults (aged 18 years and older), in the United States smoke cigarettes.¹ It is estimated that over a quarter of all strokes can be attributed to smoking.² Large epidemiological cohort studies have demonstrated that cigarette smoking is a major independent risk factor for ischemic stroke.^{3, 4, 5}

The Framingham Heart Study demonstrated that heavy smokers (>40 cigarettes/day) were twice as likely to have a stroke compared to light smokers (< 10 cigarettes/day).³ The risk of stroke decreased after two years of smoking cessation and was at the level of a non-smoker after five years of quitting.³

A meta-analysis of thirty-two studies found an increase of 50% relative risk [RR] of strokes (95% confidence interval [CI] 1.4 to 1.6) was associated with cigarette smoking.⁴ These studies provide support to the benefits of smoking cessation in patients with cerebrovascular disease. The risk of stroke declines soon after cessation among smokers regardless of age.⁵ The data from observational studies have led to the general acceptance of the benefit of smoking cessation in stroke prevention. There is a lack of interventional studies and what is less established is the relative benefit of smoking cessation interventions (SCI's) in the stroke population.

It is unclear if the effectiveness of these strategies translates to a population with cerebrovascular disease who may have motor, language or cognitive disability. The purpose of this systematic review is to present up-to-date information regarding the effectiveness of SCIs in increasing cessation rates in patients with established cerebrovascular disease.

Methods

Data sources

Studies were identified from MEDLINE (1980 to Present), EMBASE (1980 to Present) and CENTRAL (May 22, 2012) databases. The following MeSH terms were used to search the MEDLINE database: “smoking cessation”, “stop or quit or cease or cessation”, “cerebrovascular disorders”, “brain ischemia”, “transient ischemic attack”, “brain or cerebral”, “brain hemorrhage”, “brain or intracranial”, “cerebrum or cerebral”, “stroke”, “brain embolism and occlusive cerebrovascular disease”. Similar terms were used for EMBASE and CENTRAL databases.

Study selection

We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement⁶ for randomized control trials. We included studies if: 1) patients were diagnosed with cerebrovascular disease by a physician or neurologist. 2) We applied no ethnicity or age limitations in order to be as inclusive as possible. 3) We also included studies that reported smoking cessation intervention conditions (behavioural, pharmacotherapy, combination therapy). 4) Finally we excluded studies that did not report cessation rates.

Data extraction

We used a standardized form completed by two reviewers (RE, NB) independently and in duplicated extracted data from selected articles. We resolved discrepancies by consensus. Extracted data consisted of study characteristics (first author, year publication), patient

characteristics (mean age, number of smokers, type stroke diagnosis), type of SCI (behavioural, pharmacotherapy, combination), length of follow-up of the intervention and cessation rates.

Outcome of interest

The main outcome of interest was the number of patients who quit smoking either using a smoking cessation intervention versus those who did not.

Quality of assessment of primary studies

We appraised selected articles for their methodological quality and bias using the Jadad scale.⁷ The Jadad scale takes into account several methodological characteristics of clinical studies such as blinding, randomization and dropouts.⁷ Scores less than 3 were considered as low quality.

Statistical Analysis

We used a mixed model Mantel-Haenszel meta-analysis approach to combine pooled effect estimates and 95% CI's were calculated. The I^2 test was used to determine whether there was statistical heterogeneity between individual studies. Comprehensive meta-analysis 2.0 statistical software was used for the analyses.

Results

Effect of SCI on long-term quit rates

Of 852 articles identified, 4 articles were deemed to fit the inclusion criteria. Characteristics and flow of included studies can be found in Table 1 and Figure 1 respectively. The mean age of smokers was 66.5 (+/- 12.5). An overall Jadad score of the selected papers was 3.75 out of a possible score of 5. With an intervention, 42 of 153 smokers quit versus 37 of 150 in the control group. This results in an overall cessation rate of 28.1% for the intervention group compared to 24.7% for the control group. The meta-analysis revealed a non-significant effect of using a SCI on quitting (RR 1.19; 95% CI 0.81 to 1.73; $p=0.38$, $I^2=0.00$) (Figure 2).

Results of individual studies and risk of bias across studies

The first study explored the role of a patient and general practitioner systematic follow-up intervention to improve risk factor management after stroke.⁸ The study recruited 523 consecutive incident stroke survivors of which 154 (29.4%) patients were identified as smokers at baseline. They were then randomized into the control (n=78) and intervention group (n= 76). The overall intervention involved providing tailored evidence-based management advice to general practitioners, patients, and caregivers post-stroke. The advice consisted of treatment with antihypertensive therapy, treatment with antiplatelet therapy, and smoking cessation. Smoking cessation advice was provided in regards to nicotine replacement therapy (NRT) use.⁸ The authors found that at 1 year, 21/76 (27.6%) patients in the intervention group who received smoking cessation advice in regards to NRT quit smoking. In the control group at 1 year, 22/78 (28.2%) patients successfully quit smoking.⁸

The second study explored the impact of a stroke nurse specialist's input on risk factor modification.⁹ The population was selected from a clinic of ambulant patients with a diagnosis of stroke or TIA who were attending for on-going rehabilitation in a UK teaching hospital. There were 205 patients recruited of which 78 patients were identified as smokers (38%). There were 36/100 (36%) patients that were randomized into the intervention group and 42/105 (40%) were randomized into the control group. Of those randomized into the intervention group, 13/49 (26.5%) were identified as smokers. Of those randomized in the control group, 14/53 (26.4%) were identified as smokers. The intervention consisted of meetings at 3 month intervals with a

stroke nurse specialist to discuss modification of lifestyle (diet, exercise or increased activity, smoking). The control group received usual care from medical staff.⁹ Upon review of this paper, it was noted that cessation rates in the original paper were not reported. We consulted the principal investigator and cessation rates are reported here from a 3 year follow-up study from McManus and associates from the original cohort.¹⁰ Reported cessation rates in the intervention group at 42 months was found to be 1/13 (0.07%).¹⁰ None had quit in the control group (0/14).¹⁰

The third study was a pilot trial of standardized counseling and cost-free pharmacotherapy for smoking cessation in secondary stroke prevention.¹¹ Patients who have recently experienced a TIA or stroke or have been identified as being at high risk for a cerebrovascular event were recruited and were randomized to either cost-free (CF) intervention or prescription (P) control group. Patients randomized in the CF group received free of cost medications along with counseling with a smoking cessation nurse for 26 weeks.¹¹ There were 255 smokers were identified and 28 participants were enrolled based on readiness to quit. The control group received usual care and prescriptions to pharmacotherapy. Cessation rates at 26 weeks for the intervention and control group was 4/15 (26.6%) and 2/13 (15.4%) respectively.¹¹

The fourth study examined the difference between a minimal versus intensive smoking cessation intervention in increasing cessation rates in recruited patients with a recent stroke or TIA.¹² There were 94 smoking patients with a recent stroke or TIA that were recruited for this study.¹² For the purpose of this review and meta-analysis, the minimal smoking cessation intervention was considered as the control group while the intensive smoking cessation intervention was regarded as the intervention group. The control group consisted of a 30 minute counseling session with the study nurse advising patients to quit smoking.¹² A total of 45 patients were randomized into the control group.¹² The intervention group received five sessions of

1
2
3 smoking cessation counseling with the study nurse while receiving free NRT.¹² A total of 49
4 patients were randomized into the intervention group.¹² Cessation rates at 6 months for the
5 intervention and control group was 13/45 (28.9%) and 16/49 (32.7%) respectively.¹²
6
7
8
9

10 The methodological quality of each study scored collectively 3.75 out of 5 on the Jadad
11 scale. There were some limitations to each study. Sample size was an issue in all of the
12 included studies. For example the small number of participants ($n = 28$) in Papadakis et al.'s
13 study meant that the study was relatively underpowered.¹¹ Similarly, a limited number of patients
14 ($n=94$) recruited in the Frandsen et al.'s study saw little effect of the intensive smoking
15 cessation intervention.¹² A larger trial would be needed to further explore the favourable trend
16 documented in both studies. Furthermore, the provision of pharmacotherapy, counseling and
17 follow-up may be an enhancement to 'real world' standard of care experienced by TIA and
18 stroke patients. A similar underpowered result due to a small sample size was observed in the
19 study by Ellis et al./McManus et al.^{9, 10} They noted that the risk factor control in the control
20 group was better than anticipated from pilot studies and in comparison to other trial evidence. In
21 regards to study design, Ellis and associates⁹ implemented only a single blind randomization
22 design while Wolfe and colleague⁸ and Papadakis and associates¹¹ implemented a cluster
23 randomized design for their studies. It is generally accepted that the gold standard in randomized
24 control studies lie in a double-blind randomization design which was implemented by only
25 Frandsen et al.¹² Finally, all included studies recruited patients from fairly homogenous
26 sources such as 2 GP clinics,⁸ hospitals^{9, 12} and a single stroke clinic,¹¹ which may not be
27 generalizable to a broader stroke population in other settings.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **Discussion**
55
56
57
58
59
60

The purpose of this systematic review was to determine the effectiveness of SCIs in increasing cessation rates in patients with established cerebrovascular disease.

Our results demonstrate that there was a dearth of interventional studies that explore this area of stroke prevention which may have contributed to the lack of statistical significance in our meta-analyses. Furthermore, there seems to be a lack of evidence based implementation of proven SCIs. There is a link between sub-optimal use of evidence based smoking cessation medications and pharmacotherapy to poorer rates of smoking abstinence.¹¹ We found that only two of the four interventional studies^{11,12} implemented evidence based approaches to smoking cessation. The approach that these studies took fell in line with recommendations outlined in the *Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008 Update*.¹³

Fiore and associates¹³ suggested that effective smoking interventions consist of pharmacotherapy coupled with counseling and follow-up. First line pharmacotherapy such as NRT, Bupropion and Varenicline can double or even triple the likelihood of long-term smoking abstinence for heavy smokers (who consume > 10 cigarettes per day) when coupled with behavioural counseling and follow-up.¹⁴⁻¹⁶

Smoking cessation interventions have been demonstrated to be effective in other populations in particular patients with coronary heart disease (CHD). CHD patients can benefit up to an increase of 44% in their cessation rate success.¹⁷ A decrease of the risk of mortality and non-fatal myocardial infarction by 32% and 36% respectively has also been observed using this approach.¹⁸ Larger clinical studies need to employ evidence based approaches to smoking cessation to determine their effectiveness in smokers with cerebrovascular disease.

There are several limitations in the present study which should be considered in any interpretation of the findings. There was a high degree of heterogeneity among pooled data for the meta-analysis in regards to the population, intervention and outcome. There was significant variability in the population of the included studies. For example, an array of stroke diagnoses was found ranging from incident stroke and TIA. Pooled interventions also varied between studies ranging from non-specific advice on quitting and pharmacotherapy use to more specific interventions that involved the use of NRT, counseling and follow-up. The duration of interventions was also different amongst the included studies ranging from 3 to 42 months follow-up. Finally cessation was only quantified biochemically by only two studies.^{11, 12} Wolfe and associates⁸ used both biochemical assays along with self-reported smoking status to quantify cessation. However, these authors only used the biochemical assays to determine the amount of misreporting in self-reported data and did not correct misreported smoking status.⁸ Ellis and colleagues did not report how cessation was quantified.⁹

Conclusion

The paper provided results from a systematic review that explored the effectiveness of SCI's in increasing cessation rates. Evidence was found regarding the lack of interventional studies that explore this area of secondary stroke prevention. Furthermore, of those interventional studies that were found, only two studies implemented evidence-based approaches in smoking cessation. Larger studies are needed to determine how effective SCI's are in increasing cessation in smokers with established cerebrovascular disease.

Acknowledgements: None declared

Competing Interests: None declared

Funding: None declared

Contributorship statement: R. Edjoc performed primary drafting of the manuscript along with data extraction and analyses. R. Reid formulated the research question and provided feedback on the manuscript. M. Sharma provided feedback on the drafted manuscript.

Data Sharing Statement: There is no additional data available.

References

1. Centers for Disease Control and Prevention. Vital Signs: Current Cigarette Smoking Among Adults Aged ≥ 18 Years—United States, 2009. *Morbidity and Mortality Weekly Report* 2010; **59**:1135–40.
2. Hankey GJ Smoking and risk of stroke. *J. Cardiovasc Risk* 1999; **298**: 798-794.
3. Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. *JAMA* 1988; **259**:1025-1029.
4. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *BMJ* 1989; **298**: 789-794.
5. Kawachi I, Colditz, GA, Stampfer MJ, et al. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. *Ann Intern Med* 1993; **119**:992-1000.
6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. *PLoS One* 2009; **6**: e1000100. doi:10.1371/journal.pmed.1000100.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clinical Trials* 1996; **17**:1-12.
8. Wolfe CD, Redfern J, George Rudd A, et al. Cluster Randomized Controlled Trial of a Patient and General Practitioner Intervention to Improve Management of Multiple Risk Factors After Stroke: Stop Stroke. *Stroke* 2010; **41**:2470-2476.
9. Ellis G, McAlpine C, Langhorne P. The impact of stroke nurse specialist input on risk factor modification: a randomised controlled trial. *Age Ageing* 2005; **34**:389-392.
10. McManus JA, Craig A, McAlpine C, et al. Does behaviour modification affect post-stroke risk factor control? Three-year follow-up of a randomized controlled trial. *Clin Rehabil* 2009; **23**:99–105.
11. Papadakis S, Aitken D, Gocan S, et al. A pilot trial of standardized counselling and cost-free pharmacotherapy for smoking cessation in secondary stroke prevention. *BMJ Open* 2011; **1**:e000366.doi:10.1136/bmjopen-2011-000366.


12. Frandsen NB, Sørensen M, Hyldahl TK, et al. Smoking Cessation Intervention After Ischemic Stroke or Transient Ischemic Attack. A Randomized Controlled Pilot Trial. *Nicotine Tob Res* 2012; **14**: 443–447.
13. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services. *Pub Health Ser* 2008.
14. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Systematic Review* 2007; **1**:CD006103.
15. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. *Cochrane Database Systematic Review* 2008; **1**:CD000146.
16. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. *CMAJ* 2008; **179**:135-44.
17. Reid RD, Pipe AL, Quinlan B. Promoting smoking cessation during hospitalization for coronary artery disease. *Can J Cardiol* 2006; **22**:775-80.
18. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. *Cochrane Database Systematic Review* 2004; **1**:CD003041.

For peer review only

For peer review only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Figure 1: Exclusion criteria and paper selection procedure



254x190mm (300 x 300 DPI)

Figure 2: Meta-analysis of included studies



254x190mm (300 x 300 DPI)

Table 1: Characteristics of included studies

Study identification	Type of SCI/Control	Patient Characteristics	Jadad score	Cessation rate
Wolfe et al. 2010 ⁸	SCI:	Mean age: 45% over 80 yrs.Gender: 47% female	3	Nintervention =21/76 (27.6%)
	Advice on NRT use	Nsmokers= 154 (stroke survivors)		Ncontrol = 22/78 (28.2%)
	Control:			
	Usual care	Nintervention =76		
	Follow-up: 1 year	Ncontrol =78		
Ellis et al. 2005/McManus et al. 2009 ^{9, 10}	SCI:	Mean age: NR	4	Nintervention = 1/13 (0.07%)
	Discussion with nurse specialist on lifestyle modification in regards to smoking cessation	Gender:NR Nsmokers= 102 (history of stroke/TIA)		Ncontrol=0/14 (0.00%)
	Control:	Nsmokers=13/49 (26.5%; intervention)		
	Usual care	Nsmokers=14/53 (26.4%; control)		
	Follow-up: 42 months			

254x190mm (300 x 300 DPI)

Table 1: Characteristics of included studies contd.

Study identification	Type of SCI/Control	Patient Characteristics	Study Quality (Jadad score)	Cessation rate
Papadakis et al. 2011 ¹¹	SCI:	Mean age: 54.5±10.5 yrs. Gender: 70% male	4	Nintervention= 4/15 (26.6%)
	Counselling and free of cost quit smoking medications (NRT, Bupropion, Varenicline)	Nsmokers= 28 (stroke and TIA)		Ncontrol= 2/13 (15.4%)
	Control: Usual care + prescriptions to pharmacotherapy			
Frandsen et al. 2012 ¹²	Follow-up: 26 weeks SCI:	Mean age: 55.3 (SD not reported)	4	Nintervention= 16/49 (32.7%)
	Counselling and cost-free NRT (gum, tablets, patches, nasal spray)	Female: 41.5% Nsmokers=94 (stroke and TIA)		Ncontrol= 13/45 (28.9%)
	Follow-up: 6 months			

254x190mm (300 x 300 DPI)



The Effectiveness of Smoking Cessation Interventions in Smokers with Cerebrovascular Disease: A systematic review.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002022.R1
Article Type:	Research
Date Submitted by the Author:	06-Nov-2012
Complete List of Authors:	Edjoc, Rojiemiahd; University of Ottawa Heart Institute, Minto Prevention and Rehabilitation Centre Reid, Robert; University of Ottawa Heart Institute, Minto Prevention and Rehabilitation Centre Sharma, Mukul; The Ottawa Hospital, Champlain Regional Stroke Program
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Epidemiology, Smoking and tobacco
Keywords:	EPIDEMIOLOGY, systematic review, smoking cessation, Stroke < NEUROLOGY

SCHOLARONE™
Manuscripts

The Effectiveness of Smoking Cessation Interventions in Smokers with Cerebrovascular Disease: A systematic review.

Rojiemiahd K. Edjoc, MSc Ph.D¹.

Robert D. Reid, Ph.D., MBA¹

Mukul Sharma, MD MSc FRCPC²

¹Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Canada

²Regional Stroke Prevention Program, The Ottawa Hospital, Ottawa, Ontario, Canada

Correspondence to: Rojiemiahd K. Edjoc, MSc. Research Assistant, Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON K1Y 4W7, Canada

Tel: 613-983-4123

Fax: 613-761-4595

e-mail: redjoc@ottawaheart.ca

Key words: Smoking cessation, systematic review, stroke

Word count: 2927

Abstract

Objective: The main objective of this study was to determine the effectiveness of smoking cessation interventions for increasing cessation rates in smokers with cerebrovascular disease.

Design: Systematic review and meta-analyses. Two independent reviewers searched information sources and assessed studies for inclusion/exclusion criteria.

Eligibility criteria for included studies: Randomized control trials conducted prior to the 22nd of May 2012 investigating smoking cessation interventions in smokers with cerebrovascular disease were included. No age or ethnicity limitations were applied to be as inclusive as possible.

Methods: We followed the PRISMA statement approach to identify relevant randomized control studies. Due to the variability of interventions used in the reported studies, a meta-analysis was not conducted.

Results: Of 852 identified articles, 4 articles fit the inclusion criteria describing the outcome in 303 patients. The overall cessation rate with a smoking cessation intervention was 23.9% (42 out of 176) while without one was 20.8% (37 out of 178).

Conclusions: There is a limited number of reported intervention studies that explore this area of secondary stroke prevention. Furthermore, of those intervention studies that were found, only two implemented evidence based approaches to smoking cessation. A meta-analysis was not conducted due to the variability of interventions in the reported studies. Larger studies with homogenous interventions are needed to determine how effective SCIs are in increasing cessation in smokers with established cerebrovascular disease.

ARTICLE SUMMARY

Article focus

- To explore the effectiveness of smoking cessation interventions in smokers with cerebrovascular disease.

Key messages

- There are a limited number of intervention studies that explore this area of stroke prevention.
- Of those intervention studies found, only a handful employed evidence based approaches to smoking cessation.
- A meta-analysis was not conducted due to the variability of reported intervention studies.

Strengths and limitations of this study

- This is the first review to explore the effectiveness of stop smoking interventions in this high risk group of smokers.
- This review explores the breadth of potential smoking cessation interventions in stroke and TIA patients.
- Limitations of this study include a small number of available of studies, large variability in population, intervention and outcome.

Introduction

Smoking prevalence has decreased in the United States over the last 40 years and as of 2009, approximately 46 million people, or 20.6% of all adults (aged 18 years and older), in the United States smoked cigarettes.¹ It is estimated that over a quarter of all strokes can be attributed to smoking.² Large epidemiological cohort studies have demonstrated that cigarette smoking is a major independent risk factor for ischemic stroke.^{3, 4, 5}

The Framingham Heart Study demonstrated that heavy smokers (>40 cigarettes/day) were twice as likely to have a stroke compared to light smokers (between 1 and 10 cigarettes).³ The risk of stroke decreased after two years of smoking cessation and was at the level of a non-smoker after five years of quitting.³

A meta-analysis of thirty-two studies found an increase of 50% relative risk [RR] of strokes (95% confidence interval [CI] 1.4 to 1.6) was associated with cigarette smoking.⁴ These studies provide support to the benefits of smoking cessation in patients with cerebrovascular disease. The risk of stroke declines soon after cessation among smokers regardless of age.⁵ The data from observational studies have led to the general acceptance of the benefit of smoking cessation in stroke prevention. There is a lack of interventional studies and what is less established is the relative benefit of smoking cessation interventions (SCIs) in the stroke population.

The purpose of this systematic review is to present up-to-date information regarding the effectiveness of SCIs for increasing cessation rates in patients with established cerebrovascular disease.

Methods

Data sources

Studies were identified from MEDLINE (1980 to Present), EMBASE (1980 to Present) and CENTRAL (May 22, 2012) databases. The following MeSH terms were used to search the MEDLINE database: “smoking cessation”, “stop or quit or cease or cessation”, “cerebrovascular disorders”, “brain ischemia”, “transient ischemic attack”, “brain or cerebral”, “brain hemorrhage”, “brain or intracranial”, “cerebrum or cerebral”, “stroke”, “brain embolism and occlusive cerebrovascular disease”. Similar terms were used for EMBASE and CENTRAL databases.

Study selection

We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement⁶ for randomized control trials. We included studies if: 1) patients were diagnosed with cerebrovascular disease by a physician or neurologist. 2) We applied no ethnicity or age limitations in order to be as inclusive as possible. 3) We also included studies that reported smoking cessation intervention conditions (behavioural, pharmacotherapy, combination therapy). Finally, we excluded studies that did not report cessation rates.

Data extraction

We used a standardized form completed by two reviewers independently. We resolved discrepancies by consensus. Extracted data consisted of study characteristics (first author, year publication), patient characteristics (mean age, number of smokers, type of stroke diagnosis), type of SCI (behavioural, pharmacotherapy, combination), length of follow-up of the intervention and cessation rates.

Outcome of interest

The main outcome of interest was the number of patients who quit smoking either using a smoking cessation intervention versus those who did not. Cessation rates were used from follow-up data from each study. Lost to follow-up patients were included in the denominators and were considered as smokers.

Quality of assessment of primary studies

We appraised selected articles for their methodological quality and bias using the Jadad scale.⁷ The Jadad scale takes into account several methodological characteristics of clinical studies such as blinding, randomization and dropouts.⁷ Scores less than 3 were considered as low quality.

Results

Effect of SCI on long-term quit rates

Of 852 articles identified, 4 articles were deemed to fit the inclusion criteria. Characteristics and flow of included studies can be found in Table 1 and Figure 1 respectively. An overall Jadad score of the selected papers was 3.75 out of a possible score of 5. With an intervention, 42 out of 176 smokers quit versus 37 out of 178 in the control group. This resulted in an overall cessation rate of 23.9% for the intervention group compared to 20.8% for the control group.

Results of individual studies and risk of bias across studies

The first study explored the role of a patient and general practitioner systematic follow-up intervention to improve risk factor management after stroke.⁸ The study recruited 523 consecutive incident stroke survivors of which 154 (29.4%) patients were identified as smokers at baseline. They were then randomized into the control (n=78) and intervention group (n=76).

The overall intervention involved providing tailored evidence-based management advice to general practitioners, patients, and caregivers post-stroke. The advice consisted of treatment with antihypertensive therapy, treatment with antiplatelet therapy, and smoking cessation. Smoking cessation advice was provided in regards to nicotine replacement therapy (NRT) use.⁸ The authors found that at 1 year, 21 out of 76 (27.6%) patients in the intervention group who received smoking cessation advice in regards to NRT quit smoking. In the control group at 1 year, 22 out of 78 (28.2%) patients successfully quit smoking.⁸

The second study explored the impact of a stroke nurse specialist's input on risk factor modification.⁹ The population was selected from a clinic of ambulant patients with a diagnosis of stroke or TIA who were attending for on-going rehabilitation in a UK teaching hospital. There were 205 patients recruited, of which 78 patients were identified as smokers (38.0%). The intervention consisted of meetings at 3 month intervals with a stroke nurse specialist to discuss modification of lifestyle (diet, exercise or increased activity, smoking). The control group received usual care from medical staff.⁹ Upon review of this paper, it was noted that cessation rates in the original paper were not reported. We consulted the principal investigator and cessation rates are reported here from a 3 year follow-up study from McManus and associates from the original cohort.¹⁰ Reported cessation rates in the intervention group at 42 months was found to be 1 out of 36 (2.8%).¹⁰ None had quit in the control group (0 out of 42, 0.0%).¹⁰

The third study was a pilot trial of standardized counseling and cost-free pharmacotherapy for smoking cessation in secondary stroke prevention.¹¹ Patients who have recently experienced a TIA or stroke or have been identified as being at high risk for a cerebrovascular event were recruited and were randomized to either cost-free (CF) intervention or prescription (P) control group. Patients randomized in the CF group received free of cost

1
2
3 medications along with counseling with a smoking cessation nurse for 26 weeks.¹¹ There were
4
5 255 smokers were identified and 28 participants were enrolled based on readiness to quit. The
6
7 control group received usual care and prescriptions to pharmacotherapy. Cessation rates at 26
8
9 weeks for the intervention and control group was 4 out of 15 (26.6%) and 2 out of 13 (15.4%)
10
11 respectively.¹¹
12
13

14
15
16 The fourth study examined the difference between a minimal versus intensive smoking
17
18 cessation intervention in increasing cessation rates in recruited patients with a recent stroke or
19
20 TIA.¹² There were 94 smoking patients with a recent stroke or TIA that were recruited for this
21
22 study.¹² For the purpose of this review, the intensive smoking cessation intervention was
23
24 regarded as the intervention group as this would be above and beyond what would be available in
25
26 a 'real world' setting. To simplify the comparison group and due to the accessibility of smoking
27
28 cessation counseling through a primary care physician or even a smoker's helpline, the minimal
29
30 smoking cessation intervention group was considered the 'control' group. The control group
31
32 consisted of a 30 minute counseling session with the study nurse advising patients to quit
33
34 smoking.¹² A total of 45 patients were randomized into the control group.¹² The intervention
35
36 group received five sessions of smoking cessation counseling with the study nurse while
37
38 receiving free NRT.¹² A total of 49 patients were randomized into the intervention
39
40 group.¹² Cessation rates at 6 months for the intervention and control group was 16 out of 49
41
42 (32.7%) and 13 out of 45 (28.9%) respectively.¹²
43
44
45
46
47
48

49
50 There were some limitations to each study. Sample size was an issue in all of the
51
52 included studies. For example the small number of participants (n =28) in Papadakis et al.'s
53
54 study meant that the study was relatively underpowered.¹¹ Similarly, only 94 patients were
55
56 recruited in the Frandsen et al.'s study. This study saw little effect of the intensive smoking
57
58
59
60

cessation intervention.¹² A larger trial would be needed to further explore the favourable trend documented in both studies. Furthermore, the provision of pharmacotherapy, counseling and follow-up may be an enhancement to 'real world' standard of care experienced by TIA and stroke patients. A similar underpowered result due to a small sample size was observed in the study by Ellis et al./McManus et al.^{9,10} They noted that the risk factor control in the control group was better than anticipated from pilot studies and in comparison to other trial evidence. Finally, all included studies recruited patients from fairly homogenous sources such as 2 GP clinics,⁸ hospitals^{9, 12} and a single stroke clinic,¹¹ which may not be generalizable to a broader stroke population in other settings.

Discussion

The purpose of this systematic review was to determine the effectiveness of SCIs in increasing cessation rates in patients with established cerebrovascular disease.

Our results demonstrate that there were a limited number of reported interventional studies that explore this area of stroke prevention. Furthermore, there seems to be a lack of evidence based implementation of proven SCIs. There is a link between sub-optimal use of evidence based smoking cessation medications and pharmacotherapy to poorer rates of smoking abstinence.¹¹ We found that only two of the four interventional studies^{11,12} implemented evidence based approaches to smoking cessation. The approach that these studies took fell in line with recommendations outlined in the *Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008 Update*.¹³

Fiore and associates¹³ suggested that effective smoking interventions consist of pharmacotherapy coupled with counseling and follow-up. First line pharmacotherapy such as

1
2
3 NRT, Bupropion and Varenicline can double or even triple the likelihood of long-term smoking
4
5 abstinence for heavy smokers (who consume > 10 cigarettes per day) when coupled with
6
7 behavioural counseling and follow-up.¹⁴⁻¹⁶
8
9

10
11 Smoking cessation interventions have been demonstrated to be effective in other
12
13 populations in particular patients with coronary heart disease (CHD). CHD patients can benefit
14
15 up to an increase of 44% in their cessation rate success.¹⁷ A decrease of the risk of mortality and
16
17 non-fatal myocardial infarction by 32% and 36% respectively has also been observed using this
18
19 approach.¹⁸ Larger clinical studies need to employ evidence based approaches to smoking
20
21 cessation to determine their effectiveness in smokers with cerebrovascular disease.
22
23

24
25
26 There are several limitations in the present study, which should be considered in any
27
28 interpretation of the findings. There was a high degree of variability in regards to the population,
29
30 intervention and outcome. For example, an array of stroke diagnoses was found ranging from
31
32 incident stroke and TIA. A meta-analysis was not conducted due to the varied interventions from
33
34 the reported studies.. Wolfe and colleagues employed pharmacotherapy and advice on the use of
35
36 these pharmacotherapies.⁸ Ellis/McManus and associates^{9, 10} used standard outpatient advice
37
38 with post-discharge care from a nurse specialist. Papadakis and colleagues used cost-free
39
40 pharmacotherapy with counseling support and follow-up. Finally, Frandsen et al.¹¹ used
41
42 intensive counseling support with cost-free pharmacotherapy. Given these differences in
43
44 interventions and that each study was set in different countries (United Kingdom, Canada and
45
46 Denmark), would not have provided meaningful results from a meta-analysis. The duration of
47
48 follow-up was also different amongst the included studies ranging from 3 to 42 months. Finally
49
50 cessation was only quantified biochemically by only two studies.^{11, 12} Wolfe and associates⁸ used
51
52 both biochemical assays along with self-reported smoking status to quantify cessation. However,
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

these authors only used the biochemical assays to determine the amount of misreporting in self-reported data and did not correct misreported smoking status.⁸ Ellis and colleagues did not report how cessation was quantified.⁹

Conclusion

The paper provided results from a systematic review that explored the effectiveness of SCIs for increasing cessation rates. We found a limited number of reported studies that explored this area of secondary stroke prevention. Furthermore, of those interventional studies that were found, only two studies implemented evidence-based approaches in smoking cessation. A meta-analysis was not conducted due to the variability of interventions in the reported studies. Larger studies with homogenous interventions are needed to determine how effective SCIs are in increasing cessation in smokers with established cerebrovascular disease.

Acknowledgements: None declared

Competing Interests: Nonedeclared

Funding: None delcared

Contributorshipstatement: R. Edjocperformed primary drafting of the manuscript along with data extraction and analyses. R. Reid formulated the research question and provided feedback on the manuscript. M. Sharma provided feedback on the drafted manuscript. N. Bresee aided in the extraction process of data from gathered papers.

References

1. Centers for Disease Control and Prevention. Vital Signs: Current Cigarette Smoking Among Adults Aged ≥ 18 Years—United States, 2009. *Morbidity and Mortality Weekly Report* 2010; **59**:1135–40.
2. Hankey GJ. Smoking and risk of stroke. *J. Cardiovasc Risk* 1999; **298**: 798-794.
3. Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. *JAMA* 1988; **259**:1025-1029.
4. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *BMJ* 1989; **298**: 789-794.
5. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. *Ann Intern Med* 1993; **119**:992-1000.
6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. *PLoS One* 2009; **6**: e1000100. doi:10.1371/journal.pmed.1000100.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clinical Trials* 1996; **17**:1-12.
8. Wolfe CD, Redfern J, George Rudd A, et al. Cluster Randomized Controlled Trial of a Patient and General Practitioner Intervention to Improve Management of Multiple Risk Factors After Stroke: Stop Stroke. *Stroke* 2010; **41**:2470-2476.
9. Ellis G, McAlpine C, Langhorne P. The impact of stroke nurse specialist input on risk factor modification: a randomised controlled trial. *Age Ageing* 2005; **34**:389-392.
10. McManus JA, Craig A, McAlpine C, et al. Does behaviour modification affect post-stroke risk factor control? Three-year follow-up of a randomized controlled trial. *Clin Rehabil* 2009; **23**:99–105.
11. Papadakis S, Aitken D, Gocan S, et al. A pilot trial of standardized counselling and cost-free pharmacotherapy for smoking cessation in secondary stroke prevention. *BMJ Open* 2011; **1**:e000366. doi:10.1136/bmjopen-2011-000366.
12. Frandsen NB, Sørensen M, Hyldahl TK, et al. Smoking Cessation Intervention After Ischemic Stroke or Transient Ischemic Attack. A Randomized Controlled Pilot Trial. *Nicotine Tob Res* 2012; **14**: 443–447.
13. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services. *Pub Health Ser* 2008.

- 1
2
3
4
5 14. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation.
6 *Cochrane Database Systematic Review* 2007; **1**:CD006103.
7
8 15. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation.
9 *Cochrane Database Systematic Review* 2008; **1**:CD000146.
10
11 16. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-
12 analysis of randomized controlled trials. *CMAJ* 2008; **179**:135-44.
13
14 17. Reid RD, Pipe AL, Quinlan B. Promoting smoking cessation during hospitalization for
15 coronary artery disease. *Can J Cardiol* 2006; **22**:775-80.
16
17 18. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart
18 disease. *Cochrane Database Systematic Review* 2004; **1**:CD003041.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only

The Effectiveness of Smoking Cessation Interventions in Smokers with Cerebrovascular Disease: A systematic review.

Rojiemiahd K. Edjoc, MSc Ph.D¹.

Robert D. Reid, Ph.D., MBA¹

Mukul Sharma, MD MSc FRCPC²

¹Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Canada

²Regional Stroke Prevention Program, The Ottawa Hospital, Ottawa, Ontario, Canada

Correspondence to: Rojiemiahd K. Edjoc, MSc. Research Assistant, Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON K1Y 4W7, Canada

Tel: 613-983-4123

Fax: 613-761-4595

e-mail: redjoc@ottawaheart.ca

Key words: Smoking cessation, systematic review, stroke

Word count: 2927

Abstract

Objective: The main objective of this study was to determine the effectiveness of smoking cessation interventions for increasing cessation rates in smokers with cerebrovascular disease.

Design: Systematic review and meta-analyses. Two independent reviewers searched information sources and assessed studies for inclusion/exclusion criteria.

Eligibility criteria for included studies: Randomized control trials conducted prior to the 22nd of May 2012 investigating smoking cessation interventions in smokers with cerebrovascular disease were included. No age or ethnicity limitations were applied to be as inclusive as possible.

Methods: We followed the PRISMA statement approach to identify relevant randomized control studies. Due to the variability of interventions used in the reported studies, a meta-analysis was not conducted. We used a mixed-effects Mantel-Haenszel approach meta-analysis to pool estimate effects for randomized control trials.

Results: Of 852 identified articles, 4 articles fit the inclusion criteria describing the outcome in 303 patients. The overall cessation rate with a smoking cessation intervention was 23.91% (42 out of 1763) while without one was 20.84.7% (37 out of 17850). However, the meta-analysis revealed a non-significant effect of using a smoking cessation intervention on quitting (RR 1.19; 95% CI 0.81 to 1.73; p=0.38, I²=0.00).

Conclusions: There is a limited number of reported intervention studies that explore this area of secondary stroke prevention. Furthermore, of those intervention studies that were found, only two implemented evidence based approaches to smoking cessation. A meta-analysis was not conducted due to the variability of interventions in the reported studies. Larger studies with homogenous interventions are needed to determine how effective SCIs are in increasing

Formatted: Superscript

~~cessation in smokers with established cerebrovascular disease. More studies are needed to determine how effective SCI's are for increasing cessation rates in this high risk population of smokers.~~

ARTICLE SUMMARY

Article focus

- To explore the effectiveness of smoking cessation interventions in smokers with cerebrovascular disease.

Key messages

- There are a limited number of intervention studies that explore this area of stroke prevention.
- Of those intervention studies found, only a handful employed evidence based approaches to smoking cessation.
- A meta-analysis was not conducted due to the variability of reported intervention studies.

Strengths and limitations of this study

- This is the first review to explore the effectiveness of stop smoking interventions in this high risk group of smokers.
- This review explores the breadth of potential smoking cessation interventions in stroke and TIA patients.
- Limitations of this study include a small number of available of studies, large variability in population, intervention and outcome.

Introduction

Smoking prevalence has decreased in the United States over the last 40 years and as of 2009, approximately 46 million people, or 20.6% of all adults (aged 18 years and older), in the United States smoked cigarettes.¹ It is estimated that over a quarter of all strokes can be attributed to smoking.² Large epidemiological cohort studies have demonstrated that cigarette smoking is a major independent risk factor for ischemic stroke.^{3, 4, 5}

The Framingham Heart Study demonstrated that heavy smokers (>40 cigarettes/day) were twice as likely to have a stroke compared to light smokers (between 1 and 10 cigarettes/day).³ The risk of stroke decreased after two years of smoking cessation and was at the level of a non-smoker after five years of quitting.³

A meta-analysis of thirty-two studies found an increase of 50% relative risk [RR] of strokes (95% confidence interval [CI] 1.4 to 1.6) was associated with cigarette smoking.⁴ These studies provide support to the benefits of smoking cessation in patients with cerebrovascular disease. The risk of stroke declines soon after cessation among smokers regardless of age.⁵ The data from observational studies have led to the general acceptance of the benefit of smoking cessation in stroke prevention. There is a lack of interventional studies and what is less

established is the relative benefit of smoking cessation interventions (SCIs) in the stroke population.

The purpose of this systematic review is to present up-to-date information regarding the effectiveness of SCIs for increasing cessation rates in patients with established cerebrovascular disease.

Methods

Data sources

Studies were identified from MEDLINE (1980 to Present), EMBASE (1980 to Present) and CENTRAL (May 22, 2012) databases. The following MeSH terms were used to search the MEDLINE database: “smoking cessation”, “stop or quit or cease or cessation”, “cerebrovascular disorders”, “brain ischemia”, “transient ischemic attack”, “brain or cerebral”, “brain hemorrhage”, “brain or intracranial”, “cerebrum or cerebral”, “stroke”, “brain embolism and occlusive cerebrovascular disease”. Similar terms were used for EMBASE and CENTRAL databases.

Study selection

We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement⁶ for randomized control trials. We included studies if: 1) patients were diagnosed with cerebrovascular disease by a physician or neurologist. 2) We applied no ethnicity or age limitations in order to be as inclusive as possible. 3) We also included studies that reported smoking cessation intervention conditions (behavioural, pharmacotherapy, combination therapy). 4) Finally, we excluded studies that did not report cessation rates.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data extraction

We used a standardized form completed by two reviewers independently. We resolved discrepancies by consensus. Extracted data consisted of study characteristics (first author, year publication), patient characteristics (mean age, number of smokers, type of stroke diagnosis), type of SCI (behavioural, pharmacotherapy, combination), length of follow-up of the intervention and cessation rates.

Outcome of interest

The main outcome of interest was the number of patients who quit smoking either using a smoking cessation intervention versus those who did not. Cessation rates were used from follow-up data from each study. Lost to follow-up patients were included in the denominators and were considered as smokers.

Quality of assessment of primary studies

We appraised selected articles for their methodological quality and bias using the Jadad scale.⁷ The Jadad scale takes into account several methodological characteristics of clinical studies such as blinding, randomization and dropouts.⁷ Scores less than 3 were considered as low quality.

Statistical Analysis

~~We used a mixed model Mantel-Haenszel meta-analysis approach to combine pooled effect estimates and 95% CI's were calculated. The I² test was used to determine whether there was statistical heterogeneity between individual studies. Comprehensive meta-analysis 2.0 statistical software was used for the analyses.~~

Results

Effect of SCI on long-term quit rates

Of 852 articles identified, 4 articles were deemed to fit the inclusion criteria.

Characteristics and flow of included studies can be found in Table 1 and Figure 1 respectively.

~~The mean age of smokers was 66.5 (+/- 12.5).~~ An overall Jadad score of the selected papers was 3.75 out of a possible score of 5. With an intervention, 42 out of ~~176~~53 smokers quit versus 37 out of ~~178~~50 in the control group. This resulted in an overall cessation rate of ~~23.9~~28.4% for the intervention group compared to ~~20.8~~4.7% for the control group. ~~The meta-analysis revealed a non-significant effect of using a SCI on quitting (RR 1.19; 95% CI 0.81 to 1.73; p=0.38; I²=0.00) (Figure 2).~~

Results of individual studies and risk of bias across studies

The first study explored the role of a patient and general practitioner systematic follow-up intervention to improve risk factor management after stroke.⁸ The study recruited 523 consecutive incident stroke survivors of which 154 (29.4%) patients were identified as smokers at baseline. They were then randomized into the control (n=78) and intervention group (n=76). The overall intervention involved providing tailored evidence-based management advice to general practitioners, patients, and caregivers post-stroke. The advice consisted of treatment with antihypertensive therapy, treatment with antiplatelet therapy, and smoking cessation. Smoking cessation advice was provided in regards to nicotine replacement therapy (NRT) use.⁸ The authors found that at 1 year, 21 ~~out of~~ 76 (27.6%) patients in the intervention group who received smoking cessation advice in regards to NRT quit smoking. In the control group at 1 year, 22 ~~out of~~ 78 (28.2%) patients successfully quit smoking.⁸

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The second study explored the impact of a stroke nurse specialist’s input on risk factor modification.⁹ The population was selected from a clinic of ambulant patients with a diagnosis of stroke or TIA who were attending for on-going rehabilitation in a UK teaching hospital. There were 205 patients recruited, of which 78 patients were identified as smokers (38.0%). ~~There were 36/100 (36%) patients that were randomized into the intervention group and 42/105 (40%) were randomized into the control group.~~ The intervention consisted of meetings at 3 month intervals with a stroke nurse specialist to discuss modification of lifestyle (diet, exercise or increased activity, smoking). The control group received usual care from medical staff.⁹ Upon review of this paper, it was noted that cessation rates in the original paper were not reported. We consulted the principal investigator and cessation rates are reported here from a 3 year follow-up study from McManus and associates from the original cohort.¹⁰ Reported cessation rates in the intervention group at 42 months was found to be 1 ~~out of 36~~ out of 36 (72.80.07%).¹⁰ None had quit in the control group (0 ~~out of 42~~ out of 42, 0.0%¹⁴).¹⁰

The third study was a pilot trial of standardized counseling and cost-free pharmacotherapy for smoking cessation in secondary stroke prevention.¹¹ Patients who have recently experienced a TIA or stroke or have been identified as being at high risk for a cerebrovascular event were recruited and were randomized to either cost-free (CF) intervention or prescription (P) control group. Patients randomized in the CF group received free of cost medications along with counseling with a smoking cessation nurse for 26 weeks.¹¹ There were 255 smokers were identified and 28 participants were enrolled based on readiness to quit. The control group received usual care and prescriptions to pharmacotherapy. Cessation rates at 26 weeks for the intervention and control group was 4 ~~out of 15~~ out of 15 (26.6%) and 2 ~~out of 13~~ out of 13 (15.4%) respectively.¹¹

The fourth study examined the difference between a minimal versus intensive smoking cessation intervention in increasing cessation rates in recruited patients with a recent stroke or TIA.¹² There were 94 smoking patients with a recent stroke or TIA that were recruited for this study.¹² For the purpose of this review, ~~and meta-analysis, the the minimal smoking cessation intervention was considered as the control group while the~~ intensive smoking cessation intervention was regarded as the intervention group. ~~as this would be above and beyond what would be available in a 'real world' setting. To simplify the comparison group and due to the accessibility of smoking cessation counseling through a primary care physician or even a smoker's helpline, the minimal smoking cessation intervention group was considered the~~ 'control' group. The control group consisted of a 30 minute counseling session with the study nurse advising patients to quit smoking.¹² A total of 45 patients were randomized into the control group.¹² The intervention group received five sessions of smoking cessation counseling with the study nurse while receiving free NRT.¹² A total of 49 patients were randomized into the intervention group.¹² Cessation rates at 6 months for the intervention and control group was 16 out of 49 (32.7%) and 13 out of 45 (28.9%) ~~and 16/49 (32.7%)~~ respectively.¹²

~~The methodological quality of each study scored collectively 3.75 out of 5 on the Jadad scale.~~ There were some limitations to each study. Sample size was an issue in all of the included studies. For example the small number of participants (n=28) in Papadakis et al.'s study meant that the study was relatively underpowered.¹¹ Similarly, ~~only a limited 94 number of~~ patients ~~were (n=94)~~ recruited in the Frandsen et al.'s study. ~~This study~~ saw little effect of the intensive smoking cessation intervention.¹² A larger trial would be needed to further explore the favourable trend documented in both studies. Furthermore, the provision of pharmacotherapy, counseling and follow-up may be an enhancement to 'real world' standard of care experienced by TIA and

stroke patients. A similar underpowered result due to a small sample size was observed in the study by Ellis et al./McManus et al.^{9,10}. They noted that the risk factor control in the control group was better than anticipated from pilot studies and in comparison to other trial evidence. Finally, all included studies recruited patients from fairly homogenous sources such as 2 GP clinics,⁸ hospitals^{9,12} and a single stroke clinic,¹¹ which may not be generalizable to a broader stroke population in other settings.

Discussion

The purpose of this systematic review was to determine the effectiveness of SCIs in increasing cessation rates in patients with established cerebrovascular disease.

Our results demonstrate that there ~~was~~were a limited number of reported interventional studies that explore this area of stroke prevention, ~~which may have contributed to the lack of statistical significance in our meta-analyses.~~ Furthermore, there seems to be a lack of evidence based implementation of proven SCIs. There is a link between sub-optimal use of evidence based smoking cessation medications and pharmacotherapy to poorer rates of smoking abstinence.¹¹ We found that only two of the four interventional studies^{11,12} implemented evidence based approaches to smoking cessation. The approach that these studies took fell in line with recommendations outlined in the *Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008 Update*.¹³

Fiore and associates¹³ suggested that effective smoking interventions consist of pharmacotherapy coupled with counseling and follow-up. First line pharmacotherapy such as NRT, Bupropion and Varenicline can double or even triple the likelihood of long-term smoking

abstinence for heavy smokers (who consume > 10 cigarettes per day) when coupled with behavioural counseling and follow-up.¹⁴⁻¹⁶

Smoking cessation interventions have been demonstrated to be effective in other populations in particular patients with coronary heart disease (CHD). CHD patients can benefit up to an increase of 44% in their cessation rate success.¹⁷ A decrease of the risk of mortality and non-fatal myocardial infarction by 32% and 36% respectively has also been observed using this approach.¹⁸ Larger clinical studies need to employ evidence based approaches to smoking cessation to determine their effectiveness in smokers with cerebrovascular disease.

There are several limitations in the present study, which should be considered in any interpretation of the findings. There was a high degree of variability in heterogeneity among pooled data for the meta-analysis in regards to the population, intervention and outcome. There was significant variability in the population of the included studies. For example, an array of stroke diagnoses was found ranging from incident stroke and TIA. A meta-analysis was not conducted due to the varied Pooled interventions from the reported also varied between studies. Wolfe and colleagues employed pharmacotherapy and advice on the use of these pharmacotherapies (8).⁸ Ellis/McManus and associates^(9, 10) used standard outpatient advice with post-discharge care from a nurse specialist. Papadakis and colleagues used cost-free pharmacotherapy with counseling support and follow-up. Finally, Frandsen et al.⁽¹¹⁾ used intensive counseling support with cost-free pharmacotherapy. Given these differences in interventions and that each study was set in different countries (United Kingdom, Canada and Denmark), would not have provided meaningful results from a meta-analysis. The duration of follow-up was also different amongst the included studies ranging from 3 to 42 months. Finally cessation was only quantified biochemically by only two studies.^{11, 12} Wolfe and associates⁸ used

Formatted: Superscript

Formatted: Superscript

Formatted: Superscript

Formatted: Superscript

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

both biochemical assays along with self-reported smoking status to quantify cessation. However, these authors only used the biochemical assays to determine the amount of misreporting in self-reported data and did not correct misreported smoking status.⁸ Ellis and colleagues did not report how cessation was quantified.⁹

Conclusion

The paper provided results from a systematic review that explored the effectiveness of SCI²s for increasing cessation rates. We found a limited number of reported studies that explored this area of secondary stroke prevention. Furthermore, of those interventional studies that were found, only two studies implemented evidence-based approaches in smoking cessation. A meta-analysis was not conducted due to the variability of interventions in the reported studies. Larger studies with uniform homogenous interventions are needed to determine how effective SCI²s are in increasing cessation in smokers with established cerebrovascular disease.

Acknowledgements: None declared

Competing Interests: Nonedeclared

Funding: None declared

Contributorshipstatement: R. Edjocperformed primary drafting of the manuscript along with data extraction and analyses. R. Reid formulated the research question and provided feedback on the manuscript. M. Sharma provided feedback on the drafted manuscript. N. Bresee aided in the extraction process of data from gathered papers.

References

1. Centers for Disease Control and Prevention. Vital Signs: Current Cigarette Smoking Among Adults Aged ≥ 18 Years—United States, 2009. *Morbidity and Mortality Weekly Report* 2010; **59**:1135–40.
2. Hankey GJ. Smoking and risk of stroke. *J. Cardiovasc Risk* 1999; **298**: 798-794.
3. Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. *JAMA* 1988; **259**:1025-1029.
4. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *BMJ* 1989; **298**: 789-794.
5. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. *Ann Intern Med* 1993; **119**:992-1000.
6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. *PLoS One* 2009; **6**: e1000100. doi:10.1371/journal.pmed.1000100.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clinical Trials* 1996; **17**:1-12.
8. Wolfe CD, Redfern J, George Rudd A, et al. Cluster Randomized Controlled Trial of a Patient and General Practitioner Intervention to Improve Management of Multiple Risk Factors After Stroke: Stop Stroke. *Stroke* 2010; **41**:2470-2476.

9. Ellis G, McAlpine C, Langhorne P. The impact of stroke nurse specialist input on risk factor modification: a randomised controlled trial. *Age Ageing* 2005; **34**:389-392.
10. McManus JA, Craig A, McAlpine C, et al. Does behaviour modification affect post-stroke risk factor control? Three-year follow-up of a randomized controlled trial. *Clin Rehabil* 2009; **23**:99-105.
11. Papadakis S, Aitken D, Gocan S, et al. A pilot trial of standardized counselling and cost-free pharmacotherapy for smoking cessation in secondary stroke prevention. *BMJ Open* 2011; **1**:e000366. doi:10.1136/bmjopen-2011-000366.
12. Frandsen NB, Sørensen M, Hyldahl TK, et al. Smoking Cessation Intervention After Ischemic Stroke or Transient Ischemic Attack. A Randomized Controlled Pilot Trial. *Nicotine Tob Res* 2012; **14**: 443-447.
13. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services. *Pub Health Ser* 2008.
14. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Systematic Review* 2007; **1**:CD006103.
15. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. *Cochrane Database Systematic Review* 2008; **1**:CD000146.
16. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. *CMAJ* 2008; **179**:135-44.
17. Reid RD, Pipe AL, Quinlan B. Promoting smoking cessation during hospitalization for coronary artery disease. *Can J Cardiol* 2006; **22**:775-80.
18. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. *Cochrane Database Systematic Review* 2004; **1**:CD003041.

For peer review only

For peer review only

Table 1: Characteristics of included studies

Study identification	Type of SCI/Control	Patient Characteristics	Jadad score	Cessation rate
Wolfe et al. ⁸	SCI:	Intervention: 61 (22.3%) over 80 years, 126 (46.2%) female, 76 (27.9%) smokers.	3	Nintervention=21 out of 76 (27.6%)
	Advice on NRT use			
	Control:			Ncontrol=22 out of 78 (28.2%)
	Usual care	Control: 50 (20.2%) over 80 years, 118 (47.8%) female, 78 (32.2%) smokers.		
Ellis et al. ⁹ /McManus et al. ¹⁰	Follow-up: 1 year		4	
	SCI:	Intervention: 64.3 (62.4-66.1, SD) mean age, 54 (54%.0) male, 36 (36.0%) smokers.		Nintervention =1 out of 36 (2.8%)
	Discussion with nurse specialist on lifestyle modification in regards to smoking cessation	Control: 65.8 (64.0-67.5), 52 (50.0%) male, 40 (40.0%) smokers.		Ncontrol=0 out of 42 (0.0%)
	Control:			
	Usual care			
	Follow-up: 42 months			


254x190mm (300 x 300 DPI)

Table 1: Characteristics of included studies contd.

Study identification	Type of SCI/Control	Patient Characteristics	Study Quality (Jadad score)	Cessation rate
Papadakis et al. ¹¹	SCI:	Intervention: 55.4 (12.4 SD) mean age, 53.3% male, 15 (53.6%) smokers.	4	Nintervention=4 out of 15 (26.6%)
	Counseling and cost free quit smoking medications (NRT, Bupropion, Varenicline) with follow-up	Control: 53.5 (8.1 SD), mean age, 69.2% male, 13 (46.4%) smokers.		Ncontrol=2 out of 13 (15.4%)
Frandsen et al. ¹²	Control:	Usual care + prescriptions to pharmacotherapy	4	Nintervention=16 out of 49 (32.7%) Ncontrol=13 out of 45 (28.9%)
	Follow-up: 26 weeks			
	SCI:	Intervention: 29 (59.2%) age 50-65, 17 (34.7%) female, 49 smokers.		
	Counseling and cost-free NRT (gum, tablets, patches, nasal spray) with follow-up	Control: 21 (46.7%) 50-65 age, 22 (48.9%) female, 45 smokers.		
	Control:	1 time 30 min counseling support		
	Follow-up: 6 months			

254x190mm (300 x 300 DPI)

Figure 1: Exclusion criteria and paper selection procedure



254x190mm (300 x 300 DPI)



The Effectiveness of Smoking Cessation Interventions in Smokers with Cerebrovascular Disease: A systematic review.

Journal:	BMJ Open
Manuscript ID:	bmjopen-2012-002022.R2
Article Type:	Research
Date Submitted by the Author:	23-Nov-2012
Complete List of Authors:	Edjoc, Rojiemiahd; University of Ottawa Heart Institute, Minto Prevention and Rehabilitation Centre Reid, Robert; University of Ottawa Heart Institute, Minto Prevention and Rehabilitation Centre Sharma, Mukul; The Ottawa Hospital, Champlain Regional Stroke Program
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Epidemiology, Neurology
Keywords:	EPIDEMIOLOGY, systematic review, smoking cessation, Stroke < NEUROLOGY

SCHOLARONE™
Manuscripts

The Effectiveness of Smoking Cessation Interventions in Smokers with Cerebrovascular Disease: A systematic review.

Rojiemiahd K. Edjoc, MSc Ph.D¹.

Robert D. Reid, Ph.D., MBA¹

Mukul Sharma, MD MSc FRCPC²

¹Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Canada

²Regional Stroke Prevention Program, The Ottawa Hospital, Ottawa, Ontario, Canada

Correspondence to: Rojiemiahd K. Edjoc, MSc. Research Assistant, Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON K1Y 4W7, Canada

Tel: 613-983-4123

Fax: 613-761-4595

e-mail: redjoc@ottawaheart.ca

Key words: Smoking cessation, systematic review, stroke

Word count: 2932

Abstract

Objective: The main objective of this study was to determine the effectiveness of smoking cessation interventions (SCIs) for increasing cessation rates in smokers with cerebrovascular disease.

Design: Systematic review. Two independent reviewers searched information sources and assessed studies for inclusion/exclusion criteria.

Eligibility criteria for included studies: Randomized control trials conducted prior to the 22nd of May 2012 investigating smoking cessation interventions in smokers with cerebrovascular disease were included. No age or ethnicity limitations were applied to be as inclusive as possible.

Methods: We followed the PRISMA statement approach to identify relevant randomized control studies. Due to the variability of interventions used in the reported studies, a meta-analysis was not conducted.

Results: Of 852 identified articles, 4 articles fit the inclusion criteria describing the outcome in 354 patients. The overall cessation rate with a smoking cessation intervention was 23.9% (42 out of 176) while without one was 20.8% (37 out of 178).

Conclusions: There is a limited number of reported intervention studies that explore this area of secondary stroke prevention. Furthermore, of those intervention studies that were found, only two-implemented evidence based approaches to smoking cessation. A meta-analysis was not conducted due to the variability of interventions in the reported studies. Larger studies with homogenous interventions are needed to determine how effective SCIs are in increasing cessation in smokers with established cerebrovascular disease.

ARTICLE SUMMARY

Article focus

- To explore the effectiveness of smoking cessation interventions in smokers with cerebrovascular disease.

Key messages

- There are a limited number of intervention studies that explore this area of stroke prevention.
- Of those intervention studies found, only a handful employed evidence based approaches to smoking cessation.
- A meta-analysis was not conducted due to the variability of reported intervention studies.

Strengths and limitations of this study

- This is the first review to explore the effectiveness of stop smoking interventions in this high risk group of smokers.
- This review explores the breadth of potential smoking cessation interventions in stroke and transient ischemic attack (TIA) patients.
- Limitations of this study include a small number of available of studies, large variability in population, intervention and outcome.

Introduction

Smoking prevalence has decreased in the United States over the last 40 years and as of 2009, approximately 46 million people, or 20.6% of all adults (aged 18 years and older), in the United States smoked cigarettes.¹ It is estimated that over a quarter of all strokes can be attributed to smoking.² Large epidemiological cohort studies have demonstrated that cigarette smoking is a major independent risk factor for ischemic stroke.^{3, 4, 5}

The Framingham Heart Study demonstrated that heavy smokers (>40 cigarettes/day) were twice as likely to have a stroke compared to light smokers (between 1 and 10 cigarettes).³ The risk of stroke decreased after two years of smoking cessation and was at the level of a non-smoker after five years of quitting.³

A meta-analysis of thirty-two studies found an increase of 50% relative risk [RR] of strokes (95% confidence interval [CI] 1.4 to 1.6) was associated with cigarette smoking.⁴ These studies provide support to the benefits of smoking cessation in patients with cerebrovascular disease. The risk of stroke declines soon after cessation among smokers regardless of age.⁵ The data from observational studies have led to the general acceptance of the benefit of smoking cessation in stroke prevention. There is a lack of interventional studies and what is less established is the relative benefit of smoking cessation interventions (SCIs) in the stroke population.

The purpose of this systematic review is to present up-to-date information regarding the effectiveness of SCIs for increasing cessation rates in patients with established cerebrovascular disease.

Methods

Data sources

Studies were identified from MEDLINE (1980 to Present), EMBASE (1980 to Present) and CENTRAL (May 22, 2012) databases. The following MeSH terms were used to search the MEDLINE database: “smoking cessation”, “stop or quit or cease or cessation”, “cerebrovascular disorders”, “ brain ischemia”, “transient ischemic attack”, “brain or cerebral”, “brain hemorrhage”, “brain or intracranial”, “cerebrum or cerebral”, “stroke”, “ brain embolism and occlusive cerebrovascular disease”. Similar terms were used for EMBASE and CENTRAL databases.

Study selection

We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement⁶ for randomized control trials. We included studies if: 1) patients were diagnosed with cerebrovascular disease by a physician or neurologist. 2) we applied no ethnicity or age limitations in order to be as inclusive as possible. 3) we also included studies that reported smoking cessation intervention conditions (behavioural, pharmacotherapy, combination therapy). Finally, we excluded studies that did not report cessation rates.

Data extraction

We used a standardized form completed by two reviewers independently. We resolved discrepancies by consensus. Extracted data consisted of study characteristics (first author, year publication), patient characteristics (mean age, number of smokers, type of stroke diagnosis), type of SCI (behavioural, pharmacotherapy, combination), length of follow-up of the intervention and cessation rates.

Outcome of interest

The main outcome of interest was the number of patients who quit smoking either using a smoking cessation intervention versus those who did not. Cessation rates were used from follow-up data from each study. Lost to follow-up patients were included in the denominators and were considered as smokers.

Quality of assessment of primary studies

We appraised selected articles for their methodological quality and bias using the Jadad scale.⁷ The Jadad scale takes into account several methodological characteristics of clinical studies such as blinding, randomization and dropouts.⁷ Scores less than 3 were considered as low quality.

Results

Effect of SCI on long-term quit rates

Of 852 articles identified, 4 articles were deemed to fit the inclusion criteria. Characteristics and flow of included studies can be found in Table 1 and Figure 1 respectively. An overall Jadad score of the selected papers was 3.75 out of a possible score of 5. With an intervention, 42 out of 176 smokers quit versus 37 out of 178 in the control group. This resulted in an overall cessation rate of 23.9% for the intervention group compared to 20.8% for the control group.

Results of individual studies and risk of bias across studies

The first study explored the role of a patient and general practitioner systematic follow-up intervention to improve risk factor management after stroke.⁸ The study recruited 523 consecutive incident stroke survivors of which 154 (29.4%) patients were identified as smokers

at baseline. They were then randomized into the control (n=78) and intervention group (n=76). The overall intervention involved providing tailored evidence-based management advice to general practitioners, patients, and caregivers post-stroke. The advice consisted of treatment with antihypertensive therapy, treatment with antiplatelet therapy, and smoking cessation. Smoking cessation advice was provided in regards to nicotine replacement therapy (NRT) use.⁸ The authors found that at 1 year, 21 out of 76 (27.6%) patients in the intervention group who received smoking cessation advice in regards to NRT quit smoking. In the control group at 1 year, 22 out of 78 (28.2%) patients successfully quit smoking.⁸

The second study explored the impact of a stroke nurse specialist's input on risk factor modification.⁹ The population was selected from a clinic of ambulant patients with a diagnosis of stroke or TIA who were attending for on-going rehabilitation in a UK teaching hospital. There were 205 patients recruited, of which 78 patients were identified as smokers (38.0%). The intervention consisted of meetings at 3 month intervals with a stroke nurse specialist to discuss modification of lifestyle (diet, exercise or increased activity, smoking). The control group received usual care from medical staff.⁹ Upon review of this paper, it was noted that cessation rates in the original paper were not reported. We consulted the principal investigator and cessation rates are reported here from a 3 year follow-up study from McManus and associates from the original cohort.¹⁰ Reported cessation rates in the intervention group at 42 months was found to be 1 out of 36 (2.8%).¹⁰ None had quit in the control group (0 out of 42, 0.0%).¹⁰

The third study was a pilot trial of standardized counseling and cost-free pharmacotherapy for smoking cessation in secondary stroke prevention.¹¹ Patients who have recently experienced a TIA or stroke or have been identified as being at high risk for a cerebrovascular event were recruited and were randomized to either cost-free (CF) intervention

or prescription (P) control group. Patients randomized in the CF group received free of cost medications along with counseling with a smoking cessation nurse for 26 weeks.¹¹ There were 255 smokers were identified and 28 participants were enrolled based on readiness to quit. The control group received usual care and prescriptions to pharmacotherapy. Cessation rates at 26 weeks for the intervention and control group was 4 out of 15 (26.6%) and 2 out of 13 (15.4%) respectively.¹¹

The fourth study examined the difference between a minimal versus intensive smoking cessation intervention in increasing cessation rates in recruited patients with a recent stroke or TIA.¹² There were 94 smoking patients with a recent stroke or TIA that were recruited for this study.¹² For the purpose of this review, the intensive smoking cessation intervention was regarded as the intervention group as this would be above and beyond what would be available in a 'real world' setting. To simplify the comparison group and due to the accessibility of smoking cessation counseling through a primary care physician or even a smoker's helpline, the minimal smoking cessation intervention group was considered the 'control' group. The control group consisted of a 30 minute counseling session with the study nurse advising patients to quit smoking.¹² A total of 45 patients were randomized into the control group.¹² The intervention group received five sessions of smoking cessation counseling with the study nurse while receiving free NRT.¹² A total of 49 patients were randomized into the intervention group.¹² Cessation rates at 6 months for the intervention and control group was 16 out of 49 (32.7%) and 13 out of 45 (28.9%) respectively.¹²

There were some limitations to each study. Sample size was an issue in all of the included studies. For example the small number of participants (n=28) in Papadakis et al.'s study meant that the study was relatively underpowered.¹¹ Similarly, only 94 patients were

recruited in the Frandsen et al.'s study. This study saw little effect of the intensive smoking cessation intervention.¹² A larger trial would be needed to further explore the favourable trend documented in both studies. Furthermore, the provision of pharmacotherapy, counseling and follow-up may be an enhancement to 'real world' standard of care experienced by TIA and stroke patients. A similar underpowered result due to a small sample size was observed in the study by Ellis et al./McManus et al.^{9,10} They noted that the risk factor control in the control group was better than anticipated from pilot studies and in comparison to other trial evidence. Finally, all included studies recruited patients from fairly homogenous sources such as 2 GP clinics,⁸ hospitals^{9, 12} and a single stroke clinic,¹¹ which may not be generalizable to a broader stroke population in other settings.

Discussion

The purpose of this systematic review was to determine the effectiveness of SCIs in increasing cessation rates in patients with established cerebrovascular disease.

Our results demonstrate that there were a limited number of reported interventional studies that explore this area of stroke prevention. Furthermore, there seems to be a lack of evidence-based implementation of proven SCIs. There is a link between sub-optimal use of evidence-based smoking cessation medications and pharmacotherapy to poorer rates of smoking abstinence.¹¹ We found that only two of the four interventional studies^{11,12} implemented evidence based approaches to smoking cessation. The approach that these studies took fell in line with recommendations outlined in the *Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008 Update*.¹³

1
2
3 Fiore and associates¹³ suggested that effective smoking interventions consist of
4 pharmacotherapy coupled with counseling and follow-up. First line pharmacotherapy such as
5 NRT, Bupropion and Varenicline can double or even triple the likelihood of long-term smoking
6 abstinence for heavy smokers (who consume > 10 cigarettes per day) when coupled with
7 behavioural counseling and follow-up.¹⁴⁻¹⁶
8
9

10
11
12 Smoking cessation interventions have been demonstrated to be effective in other
13 populations in particular patients with coronary heart disease (CHD). CHD patients can benefit
14 up to an increase of 44% in their cessation rate success.¹⁷ A decrease of the risk of mortality and
15 non-fatal myocardial infarction by 32% and 36% respectively has also been observed using this
16 approach.¹⁸ Larger clinical studies need to employ evidence based approaches to smoking
17 cessation to determine their effectiveness in smokers with cerebrovascular disease.
18
19

20
21
22 There are several limitations in the present study, which should be considered in any
23 interpretation of the findings. There was a high degree of variability in regards to the population,
24 intervention and outcome. For example, an array of stroke diagnoses was found ranging from
25 incident stroke and TIA. A meta-analysis was not conducted due to the varied interventions from
26 the reported studies.. Wolfe and colleagues employed pharmacotherapy and advice on the use of
27 these pharmacotherapies.⁸ Ellis/McManus and associates^{9, 10} used standard outpatient advice
28 with post-discharge care from a nurse specialist. Papadakis and colleagues used cost-free
29 pharmacotherapy with counseling support and follow-up. Finally, Frandsen et al.¹¹ used
30 intensive counseling support with cost-free pharmacotherapy. Given these differences in
31 interventions and that each study was set in different countries (United Kingdom, Canada and
32 Denmark), would not have provided meaningful results from a meta-analysis. The duration of
33 follow-up was also different amongst the included studies ranging from 3 to 42 months. Finally,
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

cessation was only quantified biochemically by only two studies.^{11, 12} Wolfe and associates⁸ used both biochemical assays along with self-reported smoking status to quantify cessation. However, these authors only used the biochemical assays to determine the amount of misreporting in self-reported data and did not correct misreported smoking status.⁸ Ellis and colleagues did not report how cessation was quantified.⁹

Conclusion

The paper provided results from a systematic review that explored the effectiveness of SCIs for increasing cessation rates. We found a limited number of reported studies that explored this area of secondary stroke prevention. Furthermore, of those interventional studies that were found, only two studies implemented evidence-based approaches in smoking cessation. A meta-analysis was not conducted due to the variability of interventions in the reported studies. Larger studies with homogenous interventions are needed to determine how effective SCIs are in increasing cessation in smokers with established cerebrovascular disease.

Acknowledgements: None declared

Competing Interests: Nonedeclared

Funding: None declared

Contributorship statement: R. Edjoc performed primary drafting of the manuscript along with data extraction and analyses. R. Reid formulated the research question and provided feedback on the manuscript. M. Sharma provided feedback on the drafted manuscript. N. Bresee aided in the extraction process of data from gathered papers.

References

1. Centers for Disease Control and Prevention. Vital Signs: Current Cigarette Smoking Among Adults Aged ≥ 18 Years—United States, 2009. *Morbidity and Mortality Weekly Report* 2010; **59**:1135–40.
2. Hankey GJ. Smoking and risk of stroke. *J. Cardiovasc Risk* 1999; **298**: 798-794.
3. Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. *JAMA* 1988; **259**:1025-1029.
4. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *BMJ* 1989; **298**: 789-794.
5. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. *Ann Intern Med* 1993; **119**:992-1000.
6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. *PLoS One* 2009; **6**: e1000100. doi:10.1371/journal.pmed.1000100.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clinical Trials* 1996; **17**:1-12.
8. Wolfe CD, Redfern J, George Rudd A, et al. Cluster Randomized Controlled Trial of a Patient and General Practitioner Intervention to Improve Management of Multiple Risk Factors After Stroke: Stop Stroke. *Stroke* 2010; **41**:2470-2476.
9. Ellis G, McAlpine C, Langhorne P. The impact of stroke nurse specialist input on risk factor modification: a randomised controlled trial. *Age Ageing* 2005; **34**:389-392.
10. McManus JA, Craig A, McAlpine C, et al. Does behaviour modification affect post-stroke risk factor control? Three-year follow-up of a randomized controlled trial. *Clin Rehabil* 2009; **23**:99–105.
11. Papadakis S, Aitken D, Gocan S, et al. A pilot trial of standardized counselling and cost-free pharmacotherapy for smoking cessation in secondary stroke prevention. *BMJ Open* 2011; **1**:e000366. doi:10.1136/bmjopen-2011-000366.
12. Frandsen NB, Sørensen M, Hyldahl TK, et al. Smoking Cessation Intervention After Ischemic Stroke or Transient Ischemic Attack. A Randomized Controlled Pilot Trial. *Nicotine Tob Res* 2012; **14**: 443–447.

- 1
2
3
4
5
6 13. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update.
7 Rockville, MD: U.S. Department of Health and Human Services. *Pub Health Ser*2008.
8
9
10 14. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation.
11 *Cochrane Database Systematic Review* 2007; **1**:CD006103.
12
13 15. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation.
14 *Cochrane Database Systematic Review* 2008; **1**:CD000146.
15
16 16. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-
17 analysis of randomized controlled trials. *CMAJ* 2008; **179**:135-44.
18
19 17. Reid RD, Pipe AL, Quinlan B. Promoting smoking cessation during hospitalization for
20 coronary artery disease. *Can J Cardiol* 2006;**22**:775-80.
21
22 18. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart
23 disease. *Cochrane Database Systematic Review* 2004; **1**:CD003041.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

For peer review only

The Effectiveness of Smoking Cessation Interventions in Smokers with Cerebrovascular Disease: A systematic review.

Rojiemiahd K. Edjoc, MSc Ph.D¹.

Robert D. Reid, Ph.D., MBA¹

Mukul Sharma, MD MSc FRCPC²

¹Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Canada

²Regional Stroke Prevention Program, The Ottawa Hospital, Ottawa, Ontario, Canada

Correspondence to: Rojiemiahd K. Edjoc, MSc. Research Assistant, Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON K1Y 4W7, Canada

Tel: 613-983-4123

Fax: 613-761-4595

e-mail: redjoc@ottawaheart.ca

Key words: Smoking cessation, systematic review, stroke

Word count: ~~2927~~2932

Abstract

Objective: The main objective of this study was to determine the effectiveness of smoking cessation interventions (SCIs) for increasing cessation rates in smokers with cerebrovascular disease.

Design: Systematic review ~~and meta-analyses~~. Two independent reviewers searched information sources and assessed studies for inclusion/exclusion criteria.

Eligibility criteria for included studies: Randomized control trials conducted prior to the 22nd of May 2012 investigating smoking cessation interventions in smokers with cerebrovascular disease were included. No age or ethnicity limitations were applied to be as inclusive as possible.

Methods: We followed the PRISMA statement approach to identify relevant randomized control studies. Due to the variability of interventions used in the reported studies, a meta-analysis was not conducted. We used a mixed-effects Mantel-Haenszel approach meta-analysis to pool estimate effects for randomized control trials.

Results: Of 852 identified articles, 4 articles fit the inclusion criteria describing the outcome in 303-354 patients. The overall cessation rate with a smoking cessation intervention was 23.8-91% (42 out of 17653) while without one was 20.84-7% (37 out of 17850). However, the meta-analysis revealed a non-significant effect of using a smoking cessation intervention on quitting (RR 1.19; 95% CI 0.81 to 1.73; p=0.38, I²=0.00).

Conclusions: There is a limited number of reported intervention studies that explore this area of secondary stroke prevention. Furthermore, of those intervention studies that were found, only two implemented two implemented evidence based approaches to smoking cessation. A meta-analysis was not conducted due to the variability of interventions in the reported studies. Larger

Formatted: Superscript

studies with homogenous interventions are needed to determine how effective SCIs are in increasing cessation in smokers with established cerebrovascular disease. More studies are needed to determine how effective SCIs are for increasing cessation rates in this high risk population of smokers.

ARTICLE SUMMARY

Article focus

- To explore the effectiveness of smoking cessation interventions in smokers with cerebrovascular disease.

Key messages

- There are a limited number of intervention studies that explore this area of stroke prevention.
- Of those intervention studies found, only a handful employed evidence based approaches to smoking cessation.
- A meta-analysis was not conducted due to the variability of reported intervention studies.

Strengths and limitations of this study

- This is the first review to explore the effectiveness of stop smoking interventions in this high risk group of smokers.
- This review explores the breadth of potential smoking cessation interventions in stroke and transient ischemic attack (TIA) patients.
- Limitations of this study include a small number of available of studies, large variability in population, intervention and outcome.

Introduction

Smoking prevalence has decreased in the United States over the last 40 years and as of 2009, approximately 46 million people, or 20.6% of all adults (aged 18 years and older), in the United States smoked cigarettes.¹ It is estimated that over a quarter of all strokes can be attributed to smoking.² Large epidemiological cohort studies have demonstrated that cigarette smoking is a major independent risk factor for ischemic stroke.^{3, 4, 5}

The Framingham Heart Study demonstrated that heavy smokers (>40 cigarettes/day) were twice as likely to have a stroke compared to light smokers (between 1 and 10 cigarettes/day).³ The risk of stroke decreased after two years of smoking cessation and was at the level of a non-smoker after five years of quitting.³

A meta-analysis of thirty-two studies found an increase of 50% relative risk [RR] of strokes (95% confidence interval [CI] 1.4 to 1.6) was associated with cigarette smoking.⁴ These studies provide support to the benefits of smoking cessation in patients with cerebrovascular disease. The risk of stroke declines soon after cessation among smokers regardless of age.⁵ The data from observational studies have led to the general acceptance of the benefit of smoking cessation in stroke prevention. There is a lack of interventional studies and what is less

established is the relative benefit of smoking cessation interventions (SCIs) in the stroke population.

The purpose of this systematic review is to present up-to-date information regarding the effectiveness of SCIs for increasing cessation rates in patients with established cerebrovascular disease.

Methods

Data sources

Studies were identified from MEDLINE (1980 to Present), EMBASE (1980 to Present) and CENTRAL (May 22, 2012) databases. The following MeSH terms were used to search the MEDLINE database: “smoking cessation”, “stop or quit or cease or cessation”, “cerebrovascular disorders”, “brain ischemia”, “transient ischemic attack”, “brain or cerebral”, “brain hemorrhage”, “brain or intracranial”, “cerebrum or cerebral”, “stroke”, “brain embolism and occlusive cerebrovascular disease”. Similar terms were used for EMBASE and CENTRAL databases.

Study selection

We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement⁶ for randomized control trials. We included studies if: 1) patients were diagnosed with cerebrovascular disease by a physician or neurologist. 2) ~~w~~We applied no ethnicity or age limitations in order to be as inclusive as possible. 3) ~~w~~We also included studies that reported smoking cessation intervention conditions (behavioural, pharmacotherapy, combination therapy). ~~4~~Finally, we excluded studies that did not report cessation rates.

Data extraction

We used a standardized form completed by two reviewers independently. We resolved discrepancies by consensus. Extracted data consisted of study characteristics (first author, year publication), patient characteristics (mean age, number of smokers, type of stroke diagnosis), type of SCI (behavioural, pharmacotherapy, combination), length of follow-up of the intervention and cessation rates.

Outcome of interest

The main outcome of interest was the number of patients who quit smoking either using a smoking cessation intervention versus those who did not. Cessation rates were used from follow-up data from each study. Lost to follow-up patients were included in the denominators and were considered as smokers.

Quality of assessment of primary studies

We appraised selected articles for their methodological quality and bias using the Jadad scale.⁷ The Jadad scale takes into account several methodological characteristics of clinical studies such as blinding, randomization and dropouts.⁷ Scores less than 3 were considered as low quality.

Statistical Analysis

~~We used a mixed model Mantel-Haenszel meta-analysis approach to combine pooled effect estimates and 95% CI's were calculated. The I² test was used to determine whether there was statistical heterogeneity between individual studies. Comprehensive meta-analysis 2.0 statistical software was used for the analyses.~~

Results

Effect of SCI on long-term quit rates

Of 852 articles identified, 4 articles were deemed to fit the inclusion criteria.

Characteristics and flow of included studies can be found in Table 1 and Figure 1 respectively.

~~The mean age of smokers was 66.5 (+/- 12.5).~~ An overall Jadad score of the selected papers was 3.75 out of a possible score of 5. With an intervention, 42 out of ~~176~~53 smokers quit versus 37 out of ~~178~~50 in the control group. This resulted in an overall cessation rate of ~~23.9~~28.4% for the intervention group compared to ~~20.8~~4.7% for the control group. ~~The meta-analysis revealed a non-significant effect of using a SCI on quitting (RR 1.19; 95% CI 0.81 to 1.73; p=0.38; I²=0.00) (Figure 2).~~

Results of individual studies and risk of bias across studies

The first study explored the role of a patient and general practitioner systematic follow-up intervention to improve risk factor management after stroke.⁸ The study recruited 523 consecutive incident stroke survivors of which 154 (29.4%) patients were identified as smokers at baseline. They were then randomized into the control (n=78) and intervention group (n=76). The overall intervention involved providing tailored evidence-based management advice to general practitioners, patients, and caregivers post-stroke. The advice consisted of treatment with antihypertensive therapy, treatment with antiplatelet therapy, and smoking cessation. Smoking cessation advice was provided in regards to nicotine replacement therapy (NRT) use.⁸ The authors found that at 1 year, 21 ~~out of~~ 76 (27.6%) patients in the intervention group who received smoking cessation advice in regards to NRT quit smoking. In the control group at 1 year, 22 ~~out of~~ 78 (28.2%) patients successfully quit smoking.⁸

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The second study explored the impact of a stroke nurse specialist’s input on risk factor modification.⁹ The population was selected from a clinic of ambulant patients with a diagnosis of stroke or TIA who were attending for on-going rehabilitation in a UK teaching hospital. There were 205 patients recruited, of which 78 patients were identified as smokers (38.0%). ~~There were 36/100 (36%) patients that were randomized into the intervention group and 42/105 (40%) were randomized into the control group.~~ The intervention consisted of meetings at 3 month intervals with a stroke nurse specialist to discuss modification of lifestyle (diet, exercise or increased activity, smoking). The control group received usual care from medical staff.⁹ Upon review of this paper, it was noted that cessation rates in the original paper were not reported. We consulted the principal investigator and cessation rates are reported here from a 3 year follow-up study from McManus and associates from the original cohort.¹⁰ Reported cessation rates in the intervention group at 42 months was found to be 1 ~~out of 36~~ out of 36 (72.80.07%).¹⁰ None had quit in the control group (0 ~~out of 42~~ out of 42, 0.0%¹⁴).¹⁰

The third study was a pilot trial of standardized counseling and cost-free pharmacotherapy for smoking cessation in secondary stroke prevention.¹¹ Patients who have recently experienced a TIA or stroke or have been identified as being at high risk for a cerebrovascular event were recruited and were randomized to either cost-free (CF) intervention or prescription (P) control group. Patients randomized in the CF group received free of cost medications along with counseling with a smoking cessation nurse for 26 weeks.¹¹ There were 255 smokers were identified and 28 participants were enrolled based on readiness to quit. The control group received usual care and prescriptions to pharmacotherapy. Cessation rates at 26 weeks for the intervention and control group was 4 ~~out of 15~~ out of 15 (26.6%) and 2 ~~out of 13~~ out of 13 (15.4%) respectively.¹¹

The fourth study examined the difference between a minimal versus intensive smoking cessation intervention in increasing cessation rates in recruited patients with a recent stroke or TIA.¹² There were 94 smoking patients with a recent stroke or TIA that were recruited for this study.¹² For the purpose of this review, ~~and meta-analysis, the the minimal smoking cessation intervention was considered as the control group while the~~ intensive smoking cessation intervention was regarded as the intervention group. ~~as this would be above and beyond what would be available in a 'real world' setting. To simplify the comparison group and due to the accessibility of smoking cessation counseling through a primary care physician or even a smoker's helpline, the minimal smoking cessation intervention group was considered the~~ 'control' group. The control group consisted of a 30 minute counseling session with the study nurse advising patients to quit smoking.¹² A total of 45 patients were randomized into the control group.¹² The intervention group received five sessions of smoking cessation counseling with the study nurse while receiving free NRT.¹² A total of 49 patients were randomized into the intervention group.¹² Cessation rates at 6 months for the intervention and control group was 16 out of 49 (32.7%) and 13 out of 45 (28.9%), ~~and 16/49 (32.7%)~~ respectively.¹²

~~The methodological quality of each study scored collectively 3.75 out of 5 on the Jadad scale.~~ There were some limitations to each study. Sample size was an issue in all of the included studies. For example the small number of participants (~~n~~=28) in Papadakis et al.'s study meant that the study was relatively underpowered.¹¹ Similarly, ~~only a limited 94 number of~~ patients ~~were (n=94)~~ recruited in the Frandsen et al.'s study. This study saw little effect of the intensive smoking cessation intervention.¹² A larger trial would be needed to further explore the favourable trend documented in both studies. Furthermore, the provision of pharmacotherapy, counseling and follow-up may be an enhancement to 'real world' standard of care experienced by TIA and

stroke patients. A similar underpowered result due to a small sample size was observed in the study by Ellis et al./McManus et al.^{9,10}. They noted that the risk factor control in the control group was better than anticipated from pilot studies and in comparison to other trial evidence. Finally, all included studies recruited patients from fairly homogenous sources such as 2 GP clinics,⁸ hospitals^{9,12} and a single stroke clinic,¹¹ which may not be generalizable to a broader stroke population in other settings.

Discussion

The purpose of this systematic review was to determine the effectiveness of SCIs in increasing cessation rates in patients with established cerebrovascular disease.

Our results demonstrate that there ~~was~~were a limited number of reported interventional studies that explore this area of stroke prevention, ~~which may have contributed to the lack of statistical significance in our meta-analyses.~~ Furthermore, there seems to be a lack of ~~evidence based~~evidence-based implementation of proven SCIs. There is a link between sub-optimal use of evidence-based smoking cessation medications and pharmacotherapy to poorer rates of smoking abstinence.¹¹ We found that only two of the four interventional studies^{11,12} implemented evidence based approaches to smoking cessation. The approach that these studies took fell in line with recommendations outlined in the *Clinical Practice Guideline: Treating Tobacco Use and Dependence: 2008 Update*.¹³

Fiore and associates¹³ suggested that effective smoking interventions consist of pharmacotherapy coupled with counseling and follow-up. First line pharmacotherapy such as NRT, Bupropion and Varenicline can double or even triple the likelihood of long-term smoking

abstinence for heavy smokers (who consume > 10 cigarettes per day) when coupled with behavioural counseling and follow-up.¹⁴⁻¹⁶

Smoking cessation interventions have been demonstrated to be effective in other populations in particular patients with coronary heart disease (CHD). CHD patients can benefit up to an increase of 44% in their cessation rate success.¹⁷ A decrease of the risk of mortality and non-fatal myocardial infarction by 32% and 36% respectively has also been observed using this approach.¹⁸ Larger clinical studies need to employ evidence based approaches to smoking cessation to determine their effectiveness in smokers with cerebrovascular disease.

There are several limitations in the present study, which should be considered in any interpretation of the findings. There was a high degree of variability in heterogeneity among pooled data for the meta-analysis in regards to the population, intervention and outcome. There was significant variability in the population of the included studies. For example, an array of stroke diagnoses was found ranging from incident stroke and TIA. A meta-analysis was not conducted due to the varied Pooled interventions from the reported also varied between studies. Wolfe and colleagues employed pharmacotherapy and advice on the use of these pharmacotherapies (8).⁸ Ellis/McManus and associates^(9, 10) used standard outpatient advice with post-discharge care from a nurse specialist. Papadakis and colleagues used cost-free pharmacotherapy with counseling support and follow-up. Finally, Frandsen et al.⁽¹¹⁾ used intensive counseling support with cost-free pharmacotherapy. Given these differences in interventions and that each study was set in different countries (United Kingdom, Canada and Denmark), would not have provided meaningful results from a meta-analysis. The duration of follow-up was also different amongst the included studies ranging from 3 to 42 months. Finally, cessation was only quantified biochemically by only two studies.^{11, 12} Wolfe and associates⁸ used

Formatted: Superscript

Formatted: Superscript

Formatted: Superscript

Formatted: Superscript

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

both biochemical assays along with self-reported smoking status to quantify cessation. However, these authors only used the biochemical assays to determine the amount of misreporting in self-reported data and did not correct misreported smoking status.⁸ Ellis and colleagues did not report how cessation was quantified.⁹

Conclusion

The paper provided results from a systematic review that explored the effectiveness of SCI²s for increasing cessation rates. We found a limited number of reported studies that explored this area of secondary stroke prevention. Furthermore, of those interventional studies that were found, only two studies implemented evidence-based approaches in smoking cessation. A meta-analysis was not conducted due to the variability of interventions in the reported studies. Larger studies with uniform homogenous interventions are needed to determine how effective SCI²s are in increasing cessation in smokers with established cerebrovascular disease.

Acknowledgements: None declared

Competing Interests: Nondeclared

Funding: None declared

Contributorship statement: R. Edjoc performed primary drafting of the manuscript along with data extraction and analyses. R. Reid formulated the research question and provided feedback on the manuscript. M. Sharma provided feedback on the drafted manuscript. N. Bresee aided in the extraction process of data from gathered papers.

References


1. Centers for Disease Control and Prevention. Vital Signs: Current Cigarette Smoking Among Adults Aged ≥ 18 Years—United States, 2009. *Morbidity and Mortality Weekly Report* 2010; **59**:1135–40.
2. Hankey GJ. Smoking and risk of stroke. *J. Cardiovasc Risk* 1999; **298**: 798-794.
3. Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. *JAMA* 1988; **259**:1025-1029.
4. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *BMJ* 1989; **298**: 789-794.
5. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. *Ann Intern Med* 1993; **119**:992-1000.
6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. *PLoS One* 2009; **6**: e1000100. doi:10.1371/journal.pmed.1000100.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clinical Trials* 1996; **17**:1-12.
8. Wolfe CD, Redfern J, George Rudd A, et al. Cluster Randomized Controlled Trial of a Patient and General Practitioner Intervention to Improve Management of Multiple Risk Factors After Stroke: Stop Stroke. *Stroke* 2010; **41**:2470-2476.

9. Ellis G, McAlpine C, Langhorne P. The impact of stroke nurse specialist input on risk factor modification: a randomised controlled trial. *Age Ageing* 2005; **34**:389-392.
10. McManus JA, Craig A, McAlpine C, et al. Does behaviour modification affect post-stroke risk factor control? Three-year follow-up of a randomized controlled trial. *Clin Rehabil* 2009; **23**:99-105.
11. Papadakis S, Aitken D, Gocan S, et al. A pilot trial of standardized counselling and cost-free pharmacotherapy for smoking cessation in secondary stroke prevention. *BMJ Open* 2011; **1**:e000366. doi:10.1136/bmjopen-2011-000366.
12. Frandsen NB, Sørensen M, Hyldahl TK, et al. Smoking Cessation Intervention After Ischemic Stroke or Transient Ischemic Attack. A Randomized Controlled Pilot Trial. *Nicotine Tob Res* 2012; **14**: 443-447.
13. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services. *Pub Health Ser* 2008.
14. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Systematic Review* 2007; **1**:CD006103.
15. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. *Cochrane Database Systematic Review* 2008; **1**:CD000146.
16. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. *CMAJ* 2008; **179**:135-44.
17. Reid RD, Pipe AL, Quinlan B. Promoting smoking cessation during hospitalization for coronary artery disease. *Can J Cardiol* 2006; **22**:775-80.
18. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. *Cochrane Database Systematic Review* 2004; **1**:CD003041.

For peer review only

For peer review only

Figure 1: Exclusion criteria and paper selection procedure



254x190mm (300 x 300 DPI)

Table 1: Characteristics of included studies

Study identification	Type of SCI/Control	Patient Characteristics	Jadad score	Cessation rate
Wolfe et al. ⁸	SCI:	Intervention: 61 (22.3%) over 80 years, 126 (46.2%) female, 76 (27.9%) smokers.	3	Nintervention=21 out of 76 (27.6%)
	Advice on NRT use			
	Control:			Ncontrol=22 out of 78 (28.2%)
	Usual care	Control: 50 (20.2%) over 80 years, 118 (47.8%) female, 78 (32.2%) smokers.		
Ellis et al. ⁹ /McManus et al. ¹⁰	Follow-up: 1 year		4	
	SCI:	Intervention: 64.3 (62.4-66.1, 95% CI) mean age, 54 (54.0%) male, 36 (36.0%) smokers.		Nintervention =1 out of 36 (2.8%)
	Discussion with nurse specialist on lifestyle modification in regards to smoking cessation	Control: 65.8 (64.0-67.5 95% CI) mean age, 52 (49.5%) male, 42 (40.0%) smokers.		Ncontrol=0 out of 42 (0.0%)
	Control:			
	Usual care			
	Follow-up: 42 months			

254x190mm (300 x 300 DPI)

Table 1: Characteristics of included studies contd.

Study identification	Type of SCI/Control	Patient Characteristics	Study Quality (Jadad score)	Cessation rate
Papadakis et al. ¹¹	SCI:	Intervention: 55.4 (12.4 SD) mean age, 53.3% male, 15 (53.6%) smokers.	4	Nintervention=4 out of 15 (26.6%)
	Counseling and cost free quit smoking medications (NRT, Bupropion, Varenicline) with follow-up	Control: 53.5 (8.1 SD), mean age, 69.2% male, 13 (46.4%) smokers.		Ncontrol=2 out of 13 (15.4%)
Frandsen et al. ¹²	Control:	Usual care + prescriptions to pharmacotherapy	4	Nintervention=16 out of 49 (32.7%) Ncontrol=13 out of 45 (28.9%)
	Follow-up: 26 weeks			
	SCI:	Intervention: 29 (59.2%) age 50-65, 17 (34.7%) female, 49 smokers.		
	Counseling and cost-free NRT (gum, tablets, patches, nasal spray) with follow-up	Control: 21 (46.7%) 50-65 age, 22 (48.9%) female, 45 smokers.		
	Control:	1 time 30 min counseling support		
	Follow-up: 6 months			

254x190mm (300 x 300 DPI)